Search results for " SC66"
showing 2 items of 2 documents
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
2014
Hepatocellular carcinoma (HCC) is characterized by limited response to current drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. This was associated with alterations in cytoskeleton organization, a reduction in expression levels of E-cadherin, β-catenin and phospho-FAK, together with up-regulation of Snail protein levels. All these alterations were coupled with anoikis cell death induction. In addition, SC66 induced the production of reactive oxygen species (ROS) and DNA damage. Pre-trea…
Antitumor activity of the novel small molecule Akt inhibitor SC66 in hepatocellular carcinoma cells.
2013
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide characterized by poor and often limited or no response to current drug therapies. The PI3K/Akt/mTOR pathway is a key regulator of cell proliferation and survival. Alterations in this pathway have been reported in many types of human cancer, including HCC. It has become evident that Akt inhibitors have great potential in cancer treatment. SC66 is a new allosteric Akt inhibitor that facilitates ubiquitination of Akt, favoring its degradation via the proteasome, thus inhibiting Akt signaling. In the present study, we investigated the anticancer activity of SC66 in HCC cell lines (HepG2, Huh7, Hep3B, PLC/PRF/5 and HA22T/VG…